Browse Clinical Publication Articles by Topic

Endometrial Biopsy: What Leads to an Insufficient Sample?

In this large retrospective cohort study at a single health system, the rate of insufficient endometrial biopsies among 27,456 patients was 12.1%. The largest risk factor for an insufficient sample was postmenopausal status (adjusted odds ratio, 5.27; 95% confidence interval, 4.88-5.70). Among premenopausal women, a history of cesarean delivery (9.6% vs. 7.2%; P < 0.001) and leiomyomas (10.3% vs. 7.2%; P < 0.001) was associated with insufficient samples.

Is Routine Voiding Necessary Following Minimally Invasive Hysterectomy?

This unblinded, randomized clinical trial of patients undergoing minimally invasive benign nonurogynecologic hysterectomy with anticipated same-day discharge demonstrated that eliminating the requirement to void prior to discharge reduced time spent in the post-anesthesia care unit by 27.14 minutes (173.26 mins no void vs. 201.95 mins void; P = 0.002) without increasing the proportion of patients with postoperative urinary retention (3% void vs. 1% no void; P = 3.69).

A Closer Look at a New Low-Dose Copper IUD

This study reports on the three-year data from an ongoing Phase III study evaluating the efficacy, safety, and tolerability of a new low-dose copper intrauterine device (IUD), demonstrating low rates of expulsion and discontinuation and expanding the nonhormonal IUD options available in the United States.

Addressing Patient Opioid Use Disorder in Primary Care

Primary care providers (PCPs) play a critical role in diagnosing and treating opioid use disorder (OUD). By approaching OUD as a chronic disease, using non-stigmatizing language, and integrating team-based care, PCPs can provide accessible, effective treatment.

Sebetralstat Tablets (Ekterly)

The U.S. Food and Drug Administration has approved sebetralstat, the first oral, on-demand treatment for acute attacks of hereditary angioedema. Sebetralstat is a selective competitive, reversible plasma kallikrein inhibitor. It is distributed by KalVista Pharmaceuticals Inc as Ekterly.

Contemporary Cardiovascular Disease Deaths in Asian Americans

An analysis of a Centers for Disease Control and Prevention database has shown the cardiovascular disease mortality rate is higher in Asian Americans than in non-Asian Americans and that this excess mortality is particularly prevalent in Filipino Americans.

Fidaxomicin Is More Clinically Effective than Vancomycin for C. difficile Infection

There is a lack of real-world data on using fidaxomicin for Clostridioides difficile infection (CDI). A retrospective, single-center study found that treatment of CDI with fidaxomicin leads to reduced clinical failure compared to oral vancomycin.

SGLT2 Inhibitor Plus Aldosterone Antagonist for HFpEF: Safe? Efficacious?

A prospective, open-label, blinded outcome crossover trial of dapagliflozin plus spironolactone vs. dapagliflozin alone in patients with heart failure with preserved or mildly reduced left ventricular ejection fraction resulted in a greater reduction in natriuretic peptides, which was accompanied by a greater decline in kidney function and a rise in serum potassium.

ApoB vs. Lp(a): Which Is More Important for CAD Risk?

In U.K. Biobank participants without known atherosclerotic cardiovascular disease or diabetes or taking lipid-lowering therapy, the risk of developing coronary artery disease is best determined by apolipoprotein B particle number, but elevated lipoprotein(a) adds significant risk, so both should be considered.

The Proton Pump Inhibitor Use and Hypertension Link in Menopausal Women

In a large study, long-term use of proton pump inhibitors in menopausal women was associated with an increased risk of developing hypertension.